FocalTherics (NASDAQ:FOCL) Upgraded at Mizuho

Mizuho upgraded shares of FocalTherics (NASDAQ:FOCL) to a strong-buy rating in a research note published on Friday morning,Zacks.com reports.

FOCL has been the topic of several other research reports. Wall Street Zen lowered shares of FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of FocalTherics in a research report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.00.

FocalTherics Stock Down 0.2%

Shares of FocalTherics stock opened at $5.43 on Friday. FocalTherics has a 1 year low of $1.21 and a 1 year high of $5.64. The firm has a market cap of $203.52 million, a PE ratio of -6.70 and a beta of -0.04. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79.

FocalTherics (NASDAQ:FOCL) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The company had revenue of $20.48 million during the quarter, compared to analysts’ expectations of $19.46 million. FocalTherics had a negative return on equity of 137.61% and a negative net margin of 41.47%. As a group, equities research analysts expect that FocalTherics will post -0.78 EPS for the current year.

Insider Buying and Selling at FocalTherics

In other news, Director Joshua Levine acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $4.22 per share, with a total value of $42,200.00. Following the acquisition, the director owned 35,000 shares in the company, valued at $147,700. The trade was a 40.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 10.10% of the company’s stock.

Institutional Investors Weigh In On FocalTherics

Institutional investors have recently added to or reduced their stakes in the business. Financial Planning Navigators CORP bought a new position in FocalTherics during the fourth quarter worth about $33,000. Leonteq Securities AG bought a new stake in shares of FocalTherics in the fourth quarter valued at approximately $313,000. Kovack Advisors Inc. purchased a new stake in shares of FocalTherics during the 4th quarter valued at approximately $53,000. Rock Springs Capital Management LP lifted its stake in shares of FocalTherics by 1.3% during the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock valued at $4,233,000 after buying an additional 16,500 shares in the last quarter. Finally, Flax Pond Capital LLC bought a new position in FocalTherics in the 4th quarter worth approximately $2,623,000. 62.74% of the stock is owned by hedge funds and other institutional investors.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.